New in the August 14, 2025, issue of NEJM: CagrilintideSemaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) Cagrilintide Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) Buy Cagrisema (cagrilintide and semaglutide mix) glp 1 weight loss peptides 99% Cosmetics Grade from ECHEMI Shop ECHEMI Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Subcutaneous Cagrilintide, Semaglutide Shows Significant Weight Loss in Type 2 Diabetes Trial Pharmacy Times Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination